標的治療薬の市場規模、シェア、成長分析：タイプ別、用途別、流通チャネル別、地域別 - 産業予測 2025～2032年

標的治療薬の世界市場規模は2023年に732億米ドルと評価され、2024年の752億5,000万米ドルから2032年には938億5,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは2.8％で成長する見通しです。

生物製剤と標的治療薬の世界市場は、モノクローナル抗体の人気の高まりとバイオテクノロジーへの投資の増加により、急速な成長を遂げています。これらの標的療法は腫瘍細胞の増殖を効果的に抑制し、腫瘍学の主要治療薬として位置づけられています。オンライン薬局の成長は、これらの治療薬の販売を強化すると予想されます。さらに、ヘルスケアインフラの整備を目的とした政府の財政支援の強化も、市場拡大に大きく寄与すると思われます。2040年までに、対象となる治療ニーズの世界の症例数は2,840万件に達すると予測されます。さらに、利用可能な治療法に関する国民の意識の高まりも、市場の成長を後押ししています。しかし、標的治療に関連する副作用が市場全体の進展を阻害する可能性があるため、課題も残されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

標的治療薬市場規模：タイプ別& CAGR（2025-2032）

• 市場概要
• モノクローナル抗体
  • 血管新生阻害剤
  • HER-2標的薬剤
  • 抗CD20モノクローナル抗体
• 小分子
  • チロシンキナーゼ阻害剤
  • mTOR阻害剤
  • PARP阻害剤

標的治療薬市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 乳がん
• 大腸がん
• 白血病
• 肺がん
• リンパ腫
• 多発性硬化症
• 腎臓がん
• 滲出型加齢黄斑変性
• その他（卵巣がん、卵管がん、前立腺がん、膵臓がん）

標的治療薬市場規模：流通チャネル別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

標的治療薬市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Roche（Switzerland）
• Novartis（Switzerland）
• Pfizer（USA）
• Merck & Co.（USA）
• Bristol-Myers Squibb（USA）
• AstraZeneca（UK）
• Amgen（USA）
• GlaxoSmithKline（UK）
• Sanofi（France）
• Bayer（Germany）
• Eli Lilly and Company（USA）
• Johnson & Johnson（USA）
• AbbVie（USA）
• Takeda Pharmaceutical（Japan）
• Gilead Sciences（USA）
• Biogen（USA）
• Regeneron Pharmaceuticals（USA）
• Celgene（USA）（Acquired by Bristol-Myers Squibb）
• Incyte（USA）

結論と提言

Global Targeted Therapeutics Market size was valued at USD 73.2 billion in 2023 and is poised to grow from USD 75.25 billion in 2024 to USD 93.85 billion by 2032, growing at a CAGR of 2.8% during the forecast period (2025-2032).

The global market for biologics and targeted therapeutics is experiencing rapid growth, driven by the increasing popularity of monoclonal antibodies and rising investments in biotechnology. These targeted therapies effectively inhibit tumor cell proliferation, positioning them as leading treatments in oncology. Anticipated growth in online pharmacies is expected to enhance the sales of these therapeutic drugs. Additionally, heightened government financial support aimed at advancing healthcare infrastructure will significantly contribute to market expansion. By 2040, global cases of targeted therapeutic needs are projected to reach 28.4 million. Furthermore, growing awareness among the population about available treatments is also propelling market growth. However, challenges remain, as side effects related to targeted therapies could hinder overall market progress.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Targeted Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Targeted Therapeutics Market Segments Analysis

Global Targeted Therapeutics Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into Monoclonal Antibodies and Small Molecule. Based on Application, the market is segmented into Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Sclerosis, Renal Cancer, Wet Age-related Macular Degeneration and Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer). Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Targeted Therapeutics Market

The Global Targeted Therapeutics market is primarily driven by the rising incidence of cancer coupled with the growing disposable income of individuals. As cancer rates continue to escalate worldwide, there is an increasing demand for innovative treatment options that offer more precise targeting of cancer cells, thus providing better outcomes for patients. Additionally, as disposable incomes rise, more patients are able to afford advanced therapies and medications, fueling the market's growth. This combination of heightened cancer prevalence and improved economic conditions creates a favorable environment for the expansion of targeted therapeutics, ultimately enhancing patient care and treatment accessibility.

Restraints in the Global Targeted Therapeutics Market

The global targeted therapeutics market faces several constraints, particularly related to the side effects associated with targeted therapies and drugs. These adverse effects can vary in severity and may include reactions that impact a patient's quality of life, leading to increased discontinuation rates and reluctance among healthcare providers to prescribe these treatments. Furthermore, the complexity of managing these side effects often requires additional resources, complicating care and potentially driving up healthcare costs. As a result, these challenges can hinder market growth and limit the overall adoption of targeted therapeutics in various therapeutic areas.

Market Trends of the Global Targeted Therapeutics Market

The global targeted therapeutics market is experiencing significant growth, driven by strategic collaborations, acquisition activities, and innovative product launches among major players. Companies are focusing on expansion strategies to enhance their therapeutic offerings, with a notable push in developing complement-targeted therapies to address various diseases. For instance, PubMed Inc.'s release of upgraded therapies showcases a commitment to improving treatment efficacy and addressing complex pathological conditions. This trend indicates a robust pipeline of novel therapies aimed at personalization and precision medicine, positioning the market for sustained growth as demand for tailored treatment options continues to rise globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Targeted Therapeutics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibodies
  • Angiogenesis Inhibitors
  • HER-2 Targeted Agents
  • Anti-CD20 Monoclonal Antibodies
• Small Molecule
  • Tyrosine Kinase Inhibitors
  • mTOR Inhibitors
  • PARP Inhibitors

Global Targeted Therapeutics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Lung Cancer
• Lymphoma
• Multiple Sclerosis
• Renal Cancer
• Wet Age-related Macular Degeneration
• Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer)

Global Targeted Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Targeted Therapeutics Market Size & CAGR (2025-2032)

• North America (Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene (USA) (Acquired by Bristol-Myers Squibb)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations